CN1106701A - 药用组合物 - Google Patents

药用组合物 Download PDF

Info

Publication number
CN1106701A
CN1106701A CN94109091A CN94109091A CN1106701A CN 1106701 A CN1106701 A CN 1106701A CN 94109091 A CN94109091 A CN 94109091A CN 94109091 A CN94109091 A CN 94109091A CN 1106701 A CN1106701 A CN 1106701A
Authority
CN
China
Prior art keywords
gluconase
inhibitor
acarbose
preparation
tetrahydrolipstatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN94109091A
Other languages
English (en)
Other versions
CN1076196C (zh
Inventor
K·-D·布雷默
P·肖卢维兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1106701A publication Critical patent/CN1106701A/zh
Application granted granted Critical
Publication of CN1076196C publication Critical patent/CN1076196C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

一种含有葡萄糖甙酶和/或淀粉酶抑制剂和脂 肪酶抑制剂作为活性物质和常规药用载体的药物制 剂。

Description

本发明涉及含有葡萄糖甙酶和/或淀粉酶抑制剂和脂肪酶抑制剂作为活性物质和常规药用载体的药物制剂。
据发现这种制剂可以用于治疗肥胖症。
因此，本发明还涉及葡萄糖甙酶和/或淀粉酶抑制剂与脂肪酶抑制剂同时合用、单独使用或按时间顺序隔开使用在治疗肥胖方面的用途。
根据本发明所能应用的葡萄糖甙酶和/或淀粉酶抑制剂有例如acarbose，adiposine，voglibose（AO-128），miglitol（Bay-m-1099），emiglitate（Bay-o-1248），MDL-25637，camiglibose（MDL-73945），tendamistate，Al-3688，trestatin，pradimicin-Q和salbostatin。
脂肪酶抑制剂有：例如Tetrahydrolipstatin，lipstatin，FL-386，WAY-121898，Bay-N-3176，valilactone，esterastin，ebelactone    A，ebelactone    B和RHC    80267。
能够进行发酵制备脂肪酶抑制剂例如lipstatin或esterastin的生物量或发酵块，也可以用作为脂肪酶抑制剂。后者在例如欧洲专利EP-A    129748和美国专利USP    4189438中都有叙述。
已经知道，葡萄糖甙酶和/或淀粉酶抑制剂，例如acarbose，可以阻滞碳水化合物的消化。
也已经知道，脂肪酶抑制剂，例如tetrahydrolipstatin（orlistat），可以在肠道内对脂肪酶产生部份抑制作用。
但是，在单种药物治疗中，脂肪酶抑制剂本身结合以节食一般只能起到适度的体重减轻，而葡萄糖甙酶和/或淀粉酶抑制剂基本上起不到使体重减轻的作用。现在惊奇地发现葡萄糖甙酶和/或淀粉酶抑制剂与脂肪酶抑制剂合用却能比单种药物治疗的情况造成大得多的体重减轻。这在下述的试验中得到证明。
该试验是在两个自愿者（A和B）中分两个试验期进行的。在七天的预试期内规定A的平均日热量为2560千卡而B为1850千卡，在这期间不服任何药物。在随后的十四天主试验期中，两个自愿者每餐各给以120mg的orlistat和100mg的acarbose。并没有规定特殊的膳食，而将体力活动减至最少。这里，如在预试期中那样也规定，A的平均日热量为2185千卡，而B为2050千卡。从下表中可以看出，两个自愿者的体重减轻是很明显的。
Figure 941090914_IMG1
与此作比较，在一个安慰剂对照的十二个星期的试验期中，用orlistat（3×120mg/天）单独治疗的情况下，患者的体重减轻平均为1.8kg（即0.3kg/14天）（Int.J.Obesity    1992;16（增刊1）：16，摘要063）。
根据本发明，葡萄糖甙酶和/或淀粉酶抑制剂可以以药物制剂的形式来使用，其中也含有脂肪酶抑制剂，或者与含有脂肪酶抑制剂的制剂混合作为一种特定组合来使用。
优选使用acarbose和orlistat。
为治疗肥胖症，这些活性成份口服使用。
它们可以以每公斤体重每日约0.003mg至约20mg优选0.015mg至10mg葡萄糖甙酶和/或淀粉酶抑制剂和大约0.15mg至20mg优选0.5mg至10mg脂肪酶抑制剂的剂量服用。
用于口服的本发明制剂可以采用片剂、胶囊、溶液或乳剂的形式。
固体剂型例如片剂和胶囊剂，每一剂量单位宜包含大约0.2mg至约100mg的葡萄糖甙酶和/或淀粉酶抑制剂和10mg至200mg的脂肪酶抑制剂。
除了治疗肥胖症之外，本发明的制剂或活性物质的组合可以用于对常与肥胖相联系发生的疾病如糖尿病、高血压、高脂血症以及耐胰岛素综合症等的治疗与预防。
对于所有这些适应症，所述活性物质都可以按上述的剂量范围来使用，个别的剂量可根据所治疗的疾病的性质以及患者的年龄和情况而定，可以在医学专家所认可的范围内来确定。
本发明通过下列的实施例详述。
具下列组成的药物制剂以本身已知的方法制备：
实施例A
软明胶胶囊：每一胶囊的用量
Orlistat        60mg
中链甘油三酯        450μl
Acarbose        50mg
实施例B
硬明胶胶囊：
Acarbose        25.0mg
Orlistat        30.0mg
晶状乳糖        37.0mg
微晶纤维素        20.0mg
聚乙烯聚吡咯烷酮        8.5mg
羧甲基淀粉钠        8.5mg
滑石粉        4.5mg
硬脂酸镁        1.5mg
胶囊内充物重量        135.0mg
实施例C
片剂：
Acarbose        25.0mg
Orlistat        30.0mg
无水乳糖            118.8mg
微晶纤维素        30.0mg
聚乙烯聚吡咯烷酮        10.0mg
羧甲基纤维素        10.0mg
硬脂酸镁        1.2mg
片剂重量        225.0mg
实施例D
具有控制的活性物质释放和在胃中存留时间增长的片剂：
Acarbose        50.0mg
Orlistat        60.0mg
粉末状乳糖        70.0mg
羟丙基甲基纤维素        52.5mg
聚乙烯聚吡咯烷酮        7.5mg
滑石粉        8.0mg
硬脂酸镁        1.0mg
胶体硅酸        1.0mg
芯重        250.0mg
羟丙基甲基纤维素        2.5mg
滑石粉        1.25mg
二氧化钛        1.25mg
薄膜包衣重量        5.0mg
实施例E
用于再制的粉末：
Acarbose        100.0mg
Orlistat        120.0mg
乙基香兰素        10.0mg
天冬酰苯丙氨酸甲酯        30.0mg
喷雾法制的脱脂奶粉        4740.0mg
总计        5000.0mg

Claims (10)

1、一种含有葡萄糖甙酶和/或淀粉酶抑制剂和脂肪酶抑制剂作为活性物质和常规药用载体的药物制剂。
2、一种如权利要求1的制剂，其特征在于其中的葡萄糖甙酶和/或淀粉酶抑制剂是acarbose，adiposine，voglibose（AO-128），miglitol（Bay-m-1099），emiglitate（Bay-o-1248），MDL-25637，camiglibose（MDL-73945），tendamistate，Al-3688，trestatin，pradimicin-Q或salbostatin。
3、一种如权利要求1的制剂，其特征在于其中的脂肪酶抑制剂是tetrahydrolipstatin，lipstatin，FL-386，WAY-121898，Bay-N-3176，valilactone，esterastin，ebelactone    A，ebelactone    B或RHC80267。
4、一种如权利要求1，2或3的制剂，其特征在于它含有acarbose和tetrahydrolipstatin作为活性物质。
5、一种含有葡萄糖甙酶和/或淀粉酶抑制剂和脂肪酶抑制剂的产品，它作为一种组合制剂用于在肥胖的治疗中同时、单独或按时间顺序隔开使用。
6、一种如权利要求5的产品，其特征在于它含有在权利要求2中提出的葡萄糖甙酶和/或淀粉酶抑制剂和在权利要求3中提出的脂肪酶抑制剂，特别是acarbose和tetrahydrolipstatin。
7、一种商业包装，它含有作为药用活性物质的葡萄糖甙酶和/或淀粉酶抑制剂连同说明该药物与脂肪酶抑制剂在治疗肥胖症中如何同时、单独或按时间顺序隔开使用的联合使用说明书。
8、一种如权利要求7的商业包装，它含有acarbose连同它与tetrahydrolipstatin联合应用的说明书。
9、葡萄糖甙酶和/或淀粉酶抑制剂在制造用于治疗肥胖的与脂肪酶合用的药物制剂中的用途。
10、根据权利要求9的将acarbose与tetrahydrolipstatin联合使用。
CN94109091A 1993-08-05 1994-08-04 药用组合物 Expired - Lifetime CN1076196C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH233993 1993-08-05
CH2339/93 1993-08-05

Publications (2)

Publication Number Publication Date
CN1106701A true CN1106701A (zh) 1995-08-16
CN1076196C CN1076196C (zh) 2001-12-19

Family

ID=4231504

Family Applications (1)

Application Number Title Priority Date Filing Date
CN94109091A Expired - Lifetime CN1076196C (zh) 1993-08-05 1994-08-04 药用组合物

Country Status (24)

Country Link
US (1) US5643874A (zh)
EP (1) EP0638317B1 (zh)
JP (1) JP2780932B2 (zh)
KR (1) KR100342285B1 (zh)
CN (1) CN1076196C (zh)
AT (1) ATE190503T1 (zh)
AU (1) AU684793B2 (zh)
BR (1) BR9403170A (zh)
CA (1) CA2128044C (zh)
CZ (1) CZ286202B6 (zh)
DE (1) DE59409200D1 (zh)
DK (1) DK0638317T3 (zh)
ES (1) ES2144019T3 (zh)
GR (1) GR3033643T3 (zh)
HU (1) HU222346B1 (zh)
IL (1) IL110510A (zh)
NO (1) NO313490B1 (zh)
NZ (1) NZ264142A (zh)
PL (1) PL175997B1 (zh)
PT (1) PT638317E (zh)
RU (1) RU2141844C1 (zh)
SA (1) SA94150156B1 (zh)
TW (1) TW381025B (zh)
ZA (1) ZA945673B (zh)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100349614C (zh) * 2005-10-21 2007-11-21 南京工业大学 一种含α－淀粉酶抑制剂的固体混合物及其制备工艺和在制药中的应用
CN100352504C (zh) * 2002-11-07 2007-12-05 爱克斯国际商务集团公司 含有α－葡糖苷酶抑制剂和α－淀粉酶抑制剂的营养补充剂
CN102805744A (zh) * 2011-06-02 2012-12-05 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
CN102872062A (zh) * 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
CN107308154A (zh) * 2017-07-19 2017-11-03 重庆植恩药业有限公司 治疗或预防肥胖症以及代谢综合征的药物组合物及其应用
CN107405309A (zh) * 2014-12-17 2017-11-28 安普洛德制药公司 用于治疗肥胖症和相关代谢紊乱的奥利司他和阿卡波糖的调释组合物

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239799T3 (es) * 1997-02-05 2005-10-01 F. Hoffmann-La Roche Ag Uso de tetrahidrolipstatina en el tratamiento de la diabetes tipo ii.
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
HU9701081D0 (en) * 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
US6267952B1 (en) * 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE19802700A1 (de) * 1998-01-24 1999-07-29 Bayer Ag Verfahren zur Herstellung einer im Mund schnell zerfallenden Arzneiform, die als Wirkstoff Acarbose enthält
EP1105122B1 (en) * 1998-08-14 2005-04-27 F.Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
AU745697B2 (en) * 1998-09-08 2002-03-28 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
JP2002535288A (ja) * 1999-01-22 2002-10-22 ウンツァ ディ マリア カルメラ マラッツィータ エッセ．ア．エッセ． リポタンパク質複合体およびそれらを含む組成物
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
US6235305B1 (en) * 1999-10-29 2001-05-22 2Pro Chemical Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor
CA2358921A1 (en) * 1999-10-29 2001-05-10 John Jason Gentry Mullins Oxetanone derivatives
US6342519B2 (en) * 1999-10-29 2002-01-29 2 Pro Chemical Oxetanone derivatives
US6348492B1 (en) * 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
KR100349334B1 (ko) * 1999-12-08 2002-08-21 박관화 아카비오신 글루코실 시몬진 및 그것의 제조방법.
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
PT1307264E (pt) * 2000-07-28 2005-02-28 Hoffmann La Roche Nova composicao farmaceutica
ES2240516T3 (es) * 2000-07-28 2005-10-16 F. Hoffmann-La Roche Ag Nuevo uso de los inhibidores de lipasa.
US6849609B2 (en) * 2001-04-10 2005-02-01 James U. Morrison Method and composition for controlled release acarbose formulations
WO2003047531A2 (en) 2001-12-04 2003-06-12 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
CN1980682A (zh) 2004-05-10 2007-06-13 丹麦皇家兽医和农业学院 用于控制体重的亚麻子
US20060029567A1 (en) * 2004-08-04 2006-02-09 Bki Holding Corporation Material for odor control
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US8283312B2 (en) * 2005-02-04 2012-10-09 The Research Foundation Of State University Of New York Compositions and methods for modulating body weight and treating obesity-related disorders
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
WO2006119038A1 (en) * 2005-04-29 2006-11-09 Naturegen, Inc. Compositions and methods for controlling glucose uptake
WO2006132440A1 (ja) * 2005-06-09 2006-12-14 Takeda Pharmaceutical Company Limited 固形製剤
JP2009503050A (ja) * 2005-08-04 2009-01-29 ファイザー・リミテッド ピペリジノイル−ピロリジンおよびピペリジノイル−ピペリジン化合物
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
EP1989196B1 (en) * 2006-02-23 2013-02-13 Pfizer Limited Piperidinoylpyrrolidines as melanocortin type 4 receptor agonists
WO2008045564A2 (en) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
KR20090064478A (ko) 2006-11-13 2009-06-18 화이자 프로덕츠 인크. 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도
US20080182851A1 (en) * 2006-11-20 2008-07-31 Glenmark Pharmaceuticals S.A. Acetylene derivatives as stearoyl coa desaturase inhibitors
EP2094643B1 (en) 2006-12-01 2012-02-29 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
EP2002825B1 (en) * 2007-06-14 2013-05-22 Krka Pharmaceutical compositions comprising orlistat
WO2009033483A1 (en) 2007-09-12 2009-03-19 Københavns Universitet Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
WO2009037542A2 (en) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Spirocyclic compounds as stearoyl coa desaturase inhibitors
WO2009050720A1 (en) * 2007-10-15 2009-04-23 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
RU2010128543A (ru) 2007-12-11 2012-01-20 Сайтопатфайндер, Инк. (Jp) Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов
MX2011001405A (es) * 2008-08-06 2011-03-21 Pfizer Ltd Compuestos de diazepina y diazocano como agonistas de mc4.
JP5752359B2 (ja) * 2010-02-25 2015-07-22 富士フイルム株式会社 体重増加抑制組成物及びこれを含む食品
JP2013528172A (ja) 2010-05-21 2013-07-08 ファイザー・インク ２−フェニルベンゾイルアミド
TR201100148A2 (tr) * 2011-01-06 2012-07-23 Bi̇lgi̇ç Mahmut Stabil akarboz förmülasyonları.
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
US8252312B1 (en) * 2011-12-27 2012-08-28 David Wong Oral solid composition comprising a lipid absorption inhibitor
WO2013133685A1 (en) 2012-03-09 2013-09-12 Biotropics Malaysia Berhad Extract formulations of rhodamnia cinerea and uses thereof
CA2873087A1 (en) * 2012-05-08 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of hyperglycemia
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
FR3017536B1 (fr) 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
KR101903150B1 (ko) 2016-09-12 2018-10-01 가톨릭대학교산학협력단 퀴니자린을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
JPS5953920B2 (ja) * 1977-12-28 1984-12-27 東洋醸造株式会社 新規なアミノ糖化合物およびその製法
CA1121290A (en) * 1978-02-14 1982-04-06 Yasuji Suhara Amino sugar derivatives
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DK520784A (da) * 1984-01-21 1985-07-22 Hoechst Ag Cycliske polypeptider, deres fremstilling og anvendelse
US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
CA1329127C (en) * 1988-08-22 1994-05-03 Takao Matsuo Calcium absorption promoter
DK244090D0 (da) * 1990-10-09 1990-10-09 Novo Nordisk As Kemiske forbindelser
US5240962A (en) * 1991-04-15 1993-08-31 Takasago Institute For Interdisciplinary Science, Inc. Antiobesity and fat-reducing agents
GB9122051D0 (en) * 1991-10-17 1991-11-27 Univ Nottingham Medicines

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100352504C (zh) * 2002-11-07 2007-12-05 爱克斯国际商务集团公司 含有α－葡糖苷酶抑制剂和α－淀粉酶抑制剂的营养补充剂
CN100349614C (zh) * 2005-10-21 2007-11-21 南京工业大学 一种含α－淀粉酶抑制剂的固体混合物及其制备工艺和在制药中的应用
CN102805744A (zh) * 2011-06-02 2012-12-05 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
CN102872062A (zh) * 2011-07-13 2013-01-16 鲁南制药集团股份有限公司 一种治疗或预防肥胖症以及代谢综合症的药物组合物
CN107405309A (zh) * 2014-12-17 2017-11-28 安普洛德制药公司 用于治疗肥胖症和相关代谢紊乱的奥利司他和阿卡波糖的调释组合物
CN107405309B (zh) * 2014-12-17 2019-04-16 安普洛德制药公司 用于治疗肥胖症和相关代谢紊乱的奥利司他和阿卡波糖的调释组合物
US11975105B2 (en) 2014-12-17 2024-05-07 Empros Pharma Ab Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
CN107308154A (zh) * 2017-07-19 2017-11-03 重庆植恩药业有限公司 治疗或预防肥胖症以及代谢综合征的药物组合物及其应用

Also Published As

Publication number Publication date
CZ286202B6 (cs) 2000-02-16
AU684793B2 (en) 1998-01-08
PL175997B1 (pl) 1999-03-31
DE59409200D1 (de) 2000-04-20
JP2780932B2 (ja) 1998-07-30
RU94028653A (ru) 1996-09-10
CN1076196C (zh) 2001-12-19
BR9403170A (pt) 1995-04-18
RU2141844C1 (ru) 1999-11-27
CZ182594A3 (en) 1995-02-15
PL304557A1 (en) 1995-02-06
HUT68300A (en) 1995-06-28
AU6883994A (en) 1995-02-16
JPH0753409A (ja) 1995-02-28
NZ264142A (en) 1996-11-26
SA94150156B1 (ar) 2005-05-15
IL110510A (en) 1999-03-12
KR950005319A (ko) 1995-03-20
DK0638317T3 (da) 2000-06-26
HU9402249D0 (en) 1994-09-28
ATE190503T1 (de) 2000-04-15
CA2128044C (en) 2007-02-20
ZA945673B (en) 1995-02-07
EP0638317B1 (de) 2000-03-15
GR3033643T3 (en) 2000-10-31
NO942900L (no) 1995-02-06
NO942900D0 (zh) 1994-08-04
PT638317E (pt) 2000-07-31
IL110510A0 (en) 1994-11-11
US5643874A (en) 1997-07-01
NO313490B1 (no) 2002-10-14
KR100342285B1 (ko) 2002-10-25
CA2128044A1 (en) 1995-02-06
TW381025B (en) 2000-02-01
HU222346B1 (hu) 2003-06-28
ES2144019T3 (es) 2000-06-01
EP0638317A1 (de) 1995-02-15

Similar Documents

Publication Publication Date Title
CN1106701A (zh) 药用组合物
CN1267013C (zh) 用于改善宠物葡萄糖和胰岛素代谢的组合物
CN1100545C (zh) 增强性功能的组合物
CN1023191C (zh) 生产持续释放异丁丙苯酸制剂的方法
US5641761A (en) Preventive agent against infectious disease of crustacea
CN1141581A (zh) 适于患有球虫病动物服用的组合物
CN1121417A (zh) 珍珠牡蛎补钙制剂
CN1389265A (zh) 一种具有保健作用的中药组合物
CN1202866C (zh) 含生物质的胃肠造影剂
CN1102394C (zh) 一种含有乳酸菌素的保健品及其制备方法
CN1323661C (zh) 脂酶抑制剂的用途
CN109771424B (zh) 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
CN106943401B (zh) Haouamine类化合物在制备防治类风湿性关节炎药物中的应用
CN1045895C (zh) 复方免疫抗生素
CN1663600A (zh) 银杏叶提取物和促进脑代谢的药物组成的复方制剂及其应用
JPH0324451B2 (zh)
CN1899532A (zh) 一种防治畜禽腹泻病的药物
CN1096690A (zh) 参芪花粉药
US3737546A (en) Use of ipronidazole in combatting swine dysentery
CN1264552C (zh) 一种预防骨质疏松和延缓衰老的制剂及其制备方法
CN1182857C (zh) 提高运动能力的花粉中药复方
CN1147380A (zh) 治疗胃及十二指肠溃疡的复方胃药
CN1327386A (zh) 抗hiv感染症剂及hiv感染症的治疗方法
CN1792364A (zh) 含有司他夫定和丙戊酸或其盐的药用组合物
CN1668321A (zh) 银杏提取物用于增加肌肉质量而减少脂肪质量的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20140804

Granted publication date: 20011219